BioSpace News Archive

HTuO Biosciences announces it has joined Johnson & Johnson Innovation - JLABS as a resident virtual company.

Kyverna Therapeutics, Inc. (Kyverna) today announced the closing of its upsized initial public offering of 16,675,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,175,000 additional shares, at an initial public offering price of $22.00 per share.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.

Oragenics, Inc. announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement, pursuant to which Ms.

AlzeCure Pharma AB announced that the company will hold a live expert event on February 19 at 15:00 with Professor Henrik Zetterberg as special expert guest speaker.

Nuvalent, Inc. today announced the initiation of the Phase 2 portion of ALKOVE-1, its Phase 1/2 clinical trial of NVL-655 for patients with ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors, following alignment with the US Food and Drug Administration (FDA) on a recommended Phase 2 dose (RP2D) of 150 mg once daily (QD).

AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced the company’s decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26, 2024.

InspireMD, Inc. today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS).

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.